Article · Wikipedia archive · Last revised Jun 2, 2026

Melevodopa

Melevodopa, also known as levodopa methyl ester (LDME) and sold under the brand name Levomet, is a dopaminergic agent. It is the methyl ester of levodopa. It is used in oral tablet form as an effervescent prodrug with 250 times the water solubility of tablet levodopa. In combination with carbidopa, as melevodopa/carbidopa, it is approved for use in the treatment of Parkinson's disease.

Last revised
Jun 2, 2026
Read time
≈ 1 min
Length
226 w
Citations
5
Source
Wikipedia ↗
Melevodopa
Clinical data
Trade namesLevomet
Other namesLevodopa methyl ester; L-DOPA methyl ester; LDME; CHF-1301
ATC code
Identifiers
  • methyl (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoate
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC10H13NO4
Molar mass211.217 g·mol−1
3D model (JSmol)
  • O=C(OC)[C@@H](N)Cc1cc(O)c(O)cc1
  • InChI=1S/C10H13NO4/c1-15-10(14)7(11)4-6-2-3-8(12)9(13)5-6/h2-3,5,7,12-13H,4,11H2,1H3/t7-/m0/s1 checkY
  • Key:XBBDACCLCFWBSI-ZETCQYMHSA-N checkY
  (verify)

Melevodopa, also known as levodopa methyl ester (LDME) and sold under the brand name Levomet, is a dopaminergic agent. It is the methyl ester of levodopa.1 It is used in oral tablet form as an effervescent prodrug with 250 times the water solubility of tablet levodopa.23 In combination with carbidopa, as melevodopa/carbidopa (brand name Sirio), it is approved for use in the treatment of Parkinson's disease.45

See also

See also

References

References

  1. Buckingham J, Baggaley K, Roberts A, Szabo L (2010). Dictionary of Alkaloids with CD-ROM. CRC Press. p. 103. ISBN 978-1-4200-7770-4. Retrieved 28 September 2024.
  2. Hickey P, Stacy M (2011). "Available and emerging treatments for Parkinson's disease: a review". Drug Design, Development and Therapy. 5: 241–254. doi:10.2147/DDDT.S11836. PMC 3096539. PMID 21607020.
  3. Stocchi F, Marconi S (July 2010). "Factors associated with motor fluctuations and dyskinesia in Parkinson Disease: potential role of a new melevodopa plus carbidopa formulation (Sirio)". Clin Neuropharmacol. 33 (4): 198–203. doi:10.1097/WNF.0b013e3181de8924. PMID 20414107.
  4. "Melevodopa/carbidopa". AdisInsight. Springer Nature Switzerland AG. 23 September 2021. Retrieved 27 September 2024.
  5. "Melevodopa: Uses, Interactions, Mechanism of Action". DrugBank Online. 1 April 2015. Retrieved 27 September 2024.